Maplight Therapeutics (NASDAQ:MPLT) Director Sells $13,358.40 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 736 shares of the stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $18.15, for a total value of $13,358.40. Following the completion of the sale, the director owned 325,059 shares of the company’s stock, valued at approximately $5,899,820.85. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Maplight Therapeutics Stock Down 1.5%

NASDAQ MPLT traded down $0.28 on Tuesday, reaching $18.02. The company had a trading volume of 97,940 shares, compared to its average volume of 185,529. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $21.55. The firm’s 50-day moving average is $17.83. The firm has a market capitalization of $817.57 million and a price-to-earnings ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Wall Street Analysts Forecast Growth

MPLT has been the subject of several recent analyst reports. Stifel Nicolaus initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 target price for the company. Wall Street Zen raised Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Jefferies Financial Group began coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $32.00 price objective for the company. Leerink Partners started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, Morgan Stanley assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Maplight Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Hedge Funds Weigh In On Maplight Therapeutics

A number of hedge funds have recently bought and sold shares of MPLT. Strs Ohio bought a new stake in shares of Maplight Therapeutics in the 4th quarter worth approximately $53,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Maplight Therapeutics in the fourth quarter valued at $70,000. New York State Common Retirement Fund acquired a new position in shares of Maplight Therapeutics during the fourth quarter valued at $93,000. MetLife Investment Management LLC bought a new position in shares of Maplight Therapeutics during the fourth quarter worth about $172,000. Finally, Walleye Capital LLC acquired a new stake in shares of Maplight Therapeutics in the 4th quarter worth about $205,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.